News & Analysis as of

IP License Due Diligence Mergers

Fenwick & West LLP

IP Due Diligence Review for Life Sciences Companies: Essential Preparations for Successful Transactions

Fenwick & West LLP on

For life sciences companies preparing for potential acquisition or investment, intellectual property (IP) often represents the cornerstone of your value, making thorough preparation and strategic foresight essential for...more

Fenwick & West LLP

What Startups and Big Pharma Need to Know About AI Drug Discovery

Fenwick & West LLP on

Integrating AI tools into drug discovery introduces a mix of opportunities and challenges for startups and large pharmaceutical companies. These challenges often center on intellectual property (IP) risks, licensing...more

Orrick, Herrington & Sutcliffe LLP

Implementing IP Best Practices to Maximize Exit Value

Good corporate hygiene will not only help you prepare for an exit from Day 1 – it will also inform the value that buyers assign to your company. Sarah Schaedler and Mark Seneca discuss key considerations from a buyer’s...more

Goodwin

Life Sciences Licensing and M&A Update: Catching Up on Recent Decisions Affecting Commercially Reasonable Efforts Definitions and...

Goodwin on

Recently, the Delaware Chancery Court and the Third Circuit issued three significant decisions on key issues affecting licensing and M&A transactions in the life sciences industry....more

Morgan Lewis - Tech & Sourcing

Where’s the Money? Options for Commercializing Technology, Part 1: Open Source Software

When the topic of technology commercialization strategies comes up, the most common options typically mentioned include the sale of a technology or building a business around technology by selling products or providing...more

Sheppard Mullin Richter & Hampton LLP

Open Source-ish! What Defines Open Source and Why it Really Matters in Investments and Acquisitions

The number of different open source licenses is growing and the variation in their terms and complexity is increasing. A number of licenses that appear to be, or are commonly referred to as “open source” do not actually meet...more

American Conference Institute (ACI)

[Event] Life Sciences IP Due Diligence – Assessing, Valuing, and Commercializing IP Assets for the Life Sciences Industry -...

This event is a one-of-a-kind, interactive forum where top diligence experts will discuss best practices and strategies for executing a proper IP due diligence analysis, both for your own portfolio, and that of potential...more

7 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide